Understanding the origins of urothelial tumours

Poster Session 87

Monday 18 March 15:45 - 17:15

Location: Green Area, Room 11

Chairs: To be confirmed
M. Sanchez-Carbayo, Vitoria-Gasteiz (ES)
R. Seiler, Bern (CH)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

1211

Long noncoding RNA DANCR facilitates metastasis and proliferation in bladder cancer cells by activating IL-11-STAT3 signaling

By: Xu C., Ziyue C., Ruihui X., Ming H., Jingtong Z., Qianghua Z., Jian H., Tianxin L.
Sun Yat-sen Memorial Hospital, Dept. of Urology, Guangzhou, China

Aims and objectives of this presentation

1213

Tumor microenvironment enhances autologous mesenchymal stem cells carrying telomerase-dependent adenoviruses for metastatic cancers

By: Hu C-Y.¹, Shiau A-L.², Wu C-L.³, Shieh G-S.⁴
¹National Cheng-Kung University Hospital, Dept. of Urology, Tainan, Taiwan,
²National Cheng Kung University Medical College, Dept. of Microbiology and Immunology, Tainan, Taiwan,
³National Cheng Kung University Medical College, Dept. of Biochemistry and Molecular Biology, Tainan, Taiwan,
⁴Tainan Hospital, Dept. of Urology, Tainan, Taiwan

Aims and objectives of this presentation

1214

Immunological microenvironment of FGFR3 altered muscle-invasive bladder cancer

By: Weyerer V.¹, Stoehr R.¹, Bolenz C.², Hartmann A.¹, Erben P.³, Eckstein M.¹
¹University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Dept. of Pathology, Erlangen, Germany,
²University of Ulm, Dept. of Urology, Ulm, Germany,
³Medical Faculty Mannheim, Heidelberg University, Dept. of Urology, Mannheim, Germany

Aims and objectives of this presentation
1215  Molecular characterization of N-methyl-N-nitrosourea-induced bladder urothelial tumor in rats


1Hyogo Prefectural Nishinomiya Hospital, Dept. of Urology, Nishinomiya, Japan, 2The Johns Hopkins University School of Medicine, Dept. of Pathology, Baltimore, United States of America, 3The Johns Hopkins University School of Medicine, Dept. of Urology, Baltimore, United States of America

Aims and objectives of this presentation

1215

1216  Silibinin induced parallel activation of macroautophagy and inhibition of chaperone-mediated autophagy in bladder cancer

By: Zeng J., Fan Y., Hou T., Wu K., Chen Y., He D., Li L.
The First Affiliated Hospital of Xi'an Jiaotong University, Dept. of Urology, Xi'an, China

Aims and objectives of this presentation

1216

1217  Identification of neoantigen candidates in bladder cancer reveals negative correlation between antigen-specific immunoreactivity and inflammation


1Xinhua hospital, Shanghai Jiaotong University School of Medicine, Dept. of Urology, Shanghai, China, 2Shanghai Institute, Shanghai Jiaotong University School of Medicine, Dept. of Immunology and Microbiology, Shanghai, China, 3Tongji University, Faculty of Life Science, Shanghai, China, 4Shanghai Institute of Immunology, Shanghai Jiaotong University School of Medicine, Dept. of Immunology and Microbiology, Shanghai, China, 5Ruijin hospital, Shanghai Jiaotong University School of Medicine, Dept. of Neurology, Shanghai, China

Aims and objectives of this presentation

1217

* 1218  The expression of ANGPTL2 on tumor vessels predicts outcome in invasive bladder cancer after radical cystectomy

By: Poyet C., Buser L., Wild P., Saba K., Sulser T., Detmar M., Roudnicky F.

1University Hospital Zurich, Dept. of Urology, Zurich, Switzerland, 2University Hospital Zurich, Dept. of Pathology, Zurich, Switzerland, 3ETH Zurich, Institute of Pharmaceutical Sciences, Zurich, Switzerland

Aims and objectives of this presentation

1218
Possible molecular targeted therapy for invasive bladder cancer: Sonic hedgehog signaling inhibitor, cyclopamine

By: Shigemura K. 1, Kitagawa K. 2, Nishimoto K. 2, Yamada N. 2, Sung S. 3, Chen K. 4, Huang C. 5, Chiang Y. 4, Liu M. 4, Fujisawa M. 1
1Kobe University, Dept. of Urology, Kobe, Japan, 2Kobe University, Health Science, Kobe, Japan, 3Taipei Medical University, Ph.D. Program for Translational Medicine, Taipei, Taiwan, 4Taipei Medical University, Dept. of Urology, Taipei, Taiwan, 5Taipei Medical University, Dept. of Pediatrics, Taipei, Taiwan

Aims and objectives of this presentation
1219

Loss of CHEK2 is associated with risk of progression and worse progression-free survival in pT1 urothelial carcinoma of the bladder

By: Spachmann P.J. 1, Azzolina V. 1, Weber F. 2, Evert M. 2, Denzinger S. 1, Burger M. 1, Otto W. 1, Breyer J. 1
1University of Regensburg, Caritas St. Josef Medical Center, Dept. of Urology, Regensburg, Germany, 2University of Regensburg, Institute of Pathology, Regensburg, Germany

Aims and objectives of this presentation
1221

Beta-arrestins regulate stem cell-like phenotype and response to chemotherapy in bladder cancer

By: Hennig M.J.P. 1, Kallifatidis G. 2, Smith D. 2, Morera D. 2, Kuczyk M. 3, Kramer M. 1, Merseburger A. 1, Lokeshwar B. 2, Lokeshwar V. 2
1University of Lübeck, Dept. of Urology, Lübeck, Germany, 2Augusta University, Dept. of Biochemistry and Molecular Biology, Augusta, United States of America, 3Hanover Medical School, Dept. of Urology, Hanover, Germany

Aims and objectives of this presentation
1222

Potential new treatment for patients with bladder cancer with a high risk of progression to invasive disease

By: Van Der Pluijm G. 1, Van Der Horst G. 1, Van De Merbel A. 1, Ruigrok E. 1, Van Der Mark M.H. 1, Ploeg E. 1, Jäätela M. 2, Kruithof-De Julio M. 3, Uhm J. 1, Pelger R.C.M. 1, Bangma C.H. 4, Boormans J. 4, Zwarthoff E.C. 5
1Leiden University Medical Center, Dept. of Urology, Leiden, The Netherlands, 2Danish Cancer Society Research Center, Cell Death and Metabolism, Copenhagen, Denmark, 3University of Berne, Dept. of Urology, Bern, Switzerland, 4Erasmus Medical Center, Dept. of Urology, Rotterdam, The Netherlands, 5Erasmus Medical Center, Dept. of Pathology, Rotterdam, The Netherlands
### Aims and objectives of this presentation

1223

<table>
<thead>
<tr>
<th>1224</th>
<th>New biomarkers of bladder cancer in liquid biopsies</th>
</tr>
</thead>
</table>

By: **Do Rosário Fernandes F.J.**, **Flores J.**, **Horvatovich P.**, **Lodeiro C.**, **Martinez J.L.**, **Santos H.**, **Calais F.**, **Pinheiro L.**

1 Centro Hospitalar de Lisboa Central, Dept. of Urology, Lisbon, Portugal,
2 Faculty of Sciences and Technology, BIOSCOPE Research Group, Lisbon, Portugal,
3 Faculty of Science and Engineering, Dept. of Analytical Biochemistry Group, Groningen, The Netherlands

**Aims and objectives of this presentation**

1224

<table>
<thead>
<tr>
<th>17:05 - 17:05</th>
<th>Conclusion</th>
</tr>
</thead>
</table>

Scientific Programme - EAU19 Barcelona